Biolidics Past Earnings Performance

Past criteria checks 0/6

Biolidics has been growing earnings at an average annual rate of 0.4%, while the Medical Equipment industry saw earnings growing at 7.9% annually. Revenues have been declining at an average rate of 28.5% per year.

Key information

0.4%

Earnings growth rate

13.6%

EPS growth rate

Medical Equipment Industry Growth16.4%
Revenue growth rate-28.5%
Return on equityn/a
Net Margin-230.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Biolidics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

Catalist:8YY Revenue, expenses and earnings (SGD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241-320
30 Jun 241-320
31 Mar 240-320
31 Dec 231-220
30 Sep 231-720
30 Jun 232-820
31 Mar 233-930
31 Dec 223-930
30 Sep 222-521
30 Jun 222-521
31 Mar 222-621
31 Dec 212-621
30 Sep 213-721
30 Jun 213-831
31 Mar 216-631
31 Dec 209-531
30 Sep 209-421
30 Jun 208-311
31 Mar 205-411
31 Dec 192-521
30 Sep 192-521
30 Jun 192-511
31 Mar 192-621
31 Dec 181-621
30 Sep 181-621
30 Jun 182-621
31 Mar 182-721
31 Dec 172-721
31 Dec 162-712
31 Dec 151-812

Quality Earnings: 8YY is currently unprofitable.

Growing Profit Margin: 8YY is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 8YY is unprofitable, but has reduced losses over the past 5 years at a rate of 0.4% per year.

Accelerating Growth: Unable to compare 8YY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 8YY is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-3.8%).


Return on Equity

High ROE: 8YY's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 06:15
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biolidics Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yi Sin NgohCGS International